The providers you work with may be smart cookies, but they don’t always know compounding.

They often are unfamiliar with the laws, regs, and standards we have to adhere to, much less the threats we face. Invariably, though, those threats have implications for prescribers, too. From possible restrictions on hormones compounding to batch-size restrictions in the new USP standards to the legal assault on shortage-drug compounding by some drug manufacturers — patient access to compounded meds is threatened.

Providers need to know about those issues, and it’s up to you to keep them informed.

A new APC briefing paper can help with that. It’s titled ‘PROVIDER UPDATE: Three threats that may impede patient access to compounded medications.’ Download it and share it with the prescribers you work with — either in the APC-branded PDF form here or cut and paste the text of it into your pharmacy’s e-newsletter or other provider communication.

And don’t forget that APC provides an entire suite of topical Prescriber Briefings to which you can add your logo and share with providers. Topics range from the regulatory framework of pharmacy compounding to a brief on GFI 256 to a primer on peptide compounding (speaking of which, read below about FDA’s recent reclassification of several peptides as Category 2 substances).

These briefing docs are just another way APC is helping position you as a trusted advisor to your providers and patients. Use ’em!

— Anthony

P.S. Our APC staff has been flooded with calls and emails this past week about the new PFM credit